Guardant Health

What Guardant Health does

Guardant Health is a publicly traded precision oncology company (NASDAQ: GH) founded in 2012 and headquartered in Palo Alto, California, that develops blood-based liquid biopsy tests and data platforms to support cancer detection, treatment selection, and recurrence monitoring. Its portfolio centers on Guardant360 Liquid CDx, the largest FDA-approved liquid biopsy panel covering 740+ genes with 27 companion diagnostic indications; Shield, the first FDA-approved blood-based colorectal cancer screening test; Guardant Reveal for minimal residual disease detection; and the Guardant Infinity platform, which combines proprietary nondestructive DNA methylation technology with genomic, epigenomic, and RNA-based profiling. Underlying these tests is InfinityAI, a proprietary AI/ML platform trained on more than one million patient tests that supports biomarker discovery, clinical trial matching, and regulatory real-world evidence generation.

The company operates through a hybrid go-to-market combining enterprise field sales to oncologists and hospitals, distribution partnerships (Quest Diagnostics, Zydus, Manulife), and direct-to-consumer screening campaigns for Shield. Revenue is generated primarily through per-test payments from Medicare and commercial payers covering more than 300 million lives, with three material revenue streams: oncology laboratory testing services, cancer screening (Shield), and BioPharma Solutions for companion diagnostic development and clinical trial services. Recent regulatory catalysts include FDA approval of the expanded Guardant360 Liquid CDx and companion diagnostic indications for Boehringer Ingelheim's HERNEXEOS and Arvinas/Pfizer's VEPPANU, alongside the American Cancer Society's first-ever endorsement of a blood-based colorectal cancer screening test, all supporting FY2026 revenue guidance of $1.30-1.32 billion following Q1 2026 revenue growth of 48.3% year-over-year.

Name

Guardant Health

Legal name

Guardant Health, Inc.

Website

https://guardanthealth.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Guardant Health is a precision oncology company that develops blood-based liquid biopsy tests, including the FDA-approved Guardant360 CDx and Shield colorectal cancer screening test, to support oncologists, biopharma partners, and average-risk screening populations across the cancer care continuum.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG), Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC)

Keywords

• Liquid biopsy diagnostics
• Precision oncology testing
• Companion diagnostic services
• Blood-based cancer screening
• Multiomic genomic profiling

Headquarters

HQ city

Redwood City

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Laboratory Testing Services - Oncology: Comprehensive genomic profiling and liquid biopsy testing services for advanced cancer patients. Tests include Guardant360 CDx for treatment selection and Guardant Reveal for MRD detection. Revenue growth of 67.6% contribution to total FY2025 revenues of $982 million.
2. Cancer Screening - Shield Test: Blood-based colorectal cancer screening test for average-risk adults. Growing rapidly with approximately 150% year-over-year volume growth. Q1 2026 revenue of $35.1 million. Covered by Medicare and commercial insurers.
3. BioPharma Solutions: Partnerships with pharmaceutical companies for companion diagnostics, clinical trial services, and real-world evidence generation using Guardant Infinity platform and InfinityAI. Supports drug development and regulatory submissions.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Guardant Health fundamentally provides blood-based cancer diagnostic tests (liquid biopsies) covering the full cancer care continuum: Shield for primary colorectal cancer screening, Guardant360 Liquid CDx for comprehensive genomic profiling and companion diagnostics in advanced cancer (740+ genes, 27 CDx indications), and Guardant Reveal for minimal residual disease (MRD) detection. Tests are performed in CLIA-certified laboratories using the proprietary Guardant Infinity methylation platform and analyzed with the InfinityAI data platform. The company also partners with pharmaceutical companies for companion diagnostic co-development and real-world evidence generation.

Product overview

Guardant Health is a precision oncology company offering a unified platform of blood-based cancer tests spanning the entire cancer care continuum. The portfolio centers on Guardant Complete, combining Shield (colorectal cancer screening), Guardant360 Liquid CDx (comprehensive genomic profiling with 27 companion diagnostic indications), and Guardant Reveal (MRD detection). The Guardant Infinity platform powers these products through proprietary nondestructive DNA methylation technology, while InfinityAI provides AI/ML capabilities for biomarker discovery and clinical decision support. The architecture integrates liquid and tissue profiling, genomic and epigenomic analysis, and biopharma partnerships for drug development. Over 1,000,000 tests have been performed by 12,000 doctors to date.

Differentiator

Problem solved

Functional benefit

Brands

• Shield: FDA-approved blood test for colorectal cancer screening
• Guardant Complete
• Guardant360 CDx
• Guardant360 Liquid CDx
• Guardant Infinity
• InfinityAI

Products and services

• Shield Blood Test FDA-approved, methylation-based blood test for primary colorectal cancer screening in average-risk adults 45 and older. First FDA-approved blood-based test for primary colorectal cancer screening, providing minimally invasive early cancer detection from a routine blood draw. Detects colorectal cancers with 83% effectiveness.
• Guardant360 Liquid CDx Blood-based comprehensive genomic profiling test profiling over 740 genes with combined genomic and epigenomic profiling from a single blood draw. The largest FDA-approved liquid biopsy panel with 100x expanded footprint, delivering results in 7 days and serving as companion diagnostic for 27 indications.
• Guardant Complete Comprehensive portfolio of blood tests for patients with early and advanced-stage cancer, spanning screening, MRD detection, and treatment selection across the cancer care continuum. Combines Guardant360, Guardant Reveal, and Shield under a unified brand.
• Guardant Reveal Tissue-free minimal residual disease (MRD) assay for early-stage cancer patients. Detects residual disease after curative-intent treatment and monitors recurrence over time through ctDNA analysis.
• Guardant Infinity Proprietary non-destructive DNA methylation technology platform combining genomic, epigenomic, and RNA-based profiling for comprehensive tumor analysis through both liquid and tissue biopsy. Sold as a standalone offering to biopharma partners.
• InfinityAI AI and machine learning technology platform for biopharma enabling biomarker discovery, clinical trial matching, site identification, and regulatory evidence generation. Built on harmonized multimodal genomic and clinical data from over 1 million patient tests.
• Guardant360 TissueNext Tissue-based comprehensive molecular profiling test powered by Guardant Infinity covering 741 SNV/Indels, 34 CNVs, 28 fusions, TMB, MSI, and 47 promoter methylation regions with RNA-based fusion detection and PD-L1 analysis. Requires only 6 slides for NGS testing.
• BioPharma Solutions Biopharmaceutical industry partnerships leveraging Guardant's liquid biopsy technology for drug development, clinical trials, and companion diagnostic co-development to accelerate precision medicine development.

Quantifiable outcome

• 83% colorectal cancer detection rate with Shield test
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core, minor and regional.

• Boehringer IngelheimcoreStrategic or Co-development Partner · 11 June 2026FDA-approved Guardant360 CDx as companion diagnostic for HERNEXEOS (zongertinib tablets), the first targeted therapy for HER2-mutant advanced non-small cell lung cancer. Test identifies patients with HER2 tyrosine kinase domain activating mutations for targeted therapy eligibility.
• ManulifeminorGTM or Marketing Partner · 23 May 2026Partnership with Manulife Singapore for screening services, expanding access to Guardant Health's diagnostic tests in the Singapore market.
• Manulife SingaporeminorGTM or Marketing Partner · 12 May 2026Strategic partnership announced during Q1 2026 results for screening services expansion in Singapore market.
• Zydus LifesciencesregionalChannel Partner/ Reseller/ Distributor · 5 May 2026Partnership to launch Shield blood-based multi-cancer detection test in India, addressing India's high cancer burden where 60-70% of cases are diagnosed late. Discussions ongoing with ~10 hospital chains, wellness centers, and laboratories.
• Arvinas/Pfizer (VEPPANU)coreStrategic or Co-development Partner · 4 May 2026FDA-approved Guardant360 CDx as companion diagnostic for VEPPANU (vepdegestrant), a treatment for ER+/HER2- advanced breast cancer with ESR1 mutations. Blood-based test enables non-invasive identification of patients eligible for the targeted PROTAC therapy.
• NuvalentcoreStrategic or Co-development Partner · 30 April 2026Multi-year global strategic collaboration to develop companion diagnostics for Nuvalent's targeted cancer therapy pipeline using Guardant's tissue and liquid biopsy platform. Partnership supports Nuvalent's global clinical studies and potential regulatory approvals, with plans for co-commercialization across major global markets if approved.
• Daiichi SankyocoreStrategic or Co-development Partner · 30 March 2026Real-world evidence from Guardant Health's InfinityAI platform contributed to Japan's approval of ENHERTU for HER2-positive advanced or recurrent solid cancers. Data supplemented clinical trial results from DESTINY-PanTumor02, DESTINY-CRC02, and DESTINY-Lung01 studies.
• Verana HealthcoreStrategic or Co-development Partner · 24 March 2026Partnership to combine Verana's regulatory-grade EHR curated datasets with Guardant's clinicogenomic testing data for precision medicine research. Enables biopharmaceutical researchers to study correlations between molecular biomarkers, treatment decisions, and clinical outcomes across bladder, lung, breast, and colorectal cancers.
• Quest DiagnosticscoreChannel Partner/ Reseller/ DistributorStrategic partnership with Quest Diagnostics for broader market distribution of diagnostic services. Leverages Quest's extensive laboratory network for increased market reach.
• PfizercoreStrategic or Co-development PartnerCollaboration on 38 abstracts presented at 2026 ASCO Annual Meeting, including oral presentation in partnership with Pfizer validating Guardant360 Liquid CDx as companion diagnostic for pan-cancer tumor profiling.
• MerckcoreStrategic or Co-development PartnerMulti-year collaboration with Merck targeting biomarker discovery and trial enrollment for oncology drugs using Guardant's diagnostic platforms.
• Johnson & Johnson (UAE Initiative)minorGTM or Marketing PartnerJ&J launched initiative in UAE supporting access to Guardant Health liquid biopsy testing for advanced NSCLC patients whose insurance may not cover the diagnostic test.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Direct competitor to Guardant360 Liquid CDx in oncology therapy selection and companion diagnostics, with deeper NCCN guideline entrenchment and pharma integration.
• Natera: Specializes in cell-free DNA testing, with Signatera as a leading tumor-informed MRD assay directly competing with Guardant Reveal. Overlapping oncology and reproductive health liquid biopsy focus with comparable technology and customer base.
• NeoGenomics: Oncology-focused clinical laboratory offering comprehensive solid tumor and liquid biopsy profiling (RaDaR MRD assay). Comparable business model as a fee-for-service oncology reference lab serving oncologists, hospitals, and pharma clients.
• Exact Sciences: Cologuard franchise leader in non-invasive CRC screening with a competing blood-based CRC test (Shield) being developed. Overlap with Guardant in oncology screening, particularly CRC, with deep commercial reach to primary care and payor relationships.
• Tempus AI: AI-powered precision medicine company offering multi-modal oncology testing (Tempus xT, xR, xF) and a large clinicogenomic data platform. Competes directly with Guardant's Guardant360 profiling and InfinityAI analytics services for biopharma RWE and CDx development.
• Veracyte: Genomic diagnostics company expanding into oncology with the Decipher Prostate and other tests. Recent Affirma and HalioDx acquisitions position Veracyte as a growing competitor in oncology testing, including in urologic oncology where Guardant also operates.

Emerging players

• Caris Life Sciences: Emerging competitor in molecular profiling (MI Profile, MI Cancer Seek) with both tissue and liquid biopsy offerings. Increasingly relevant as a direct peer for therapy selection and multi-cancer screening programs overlapping Guardant's portfolio.
• Personalis: Smaller oncology genomics company offering NeXT Personal (tumor-informed MRD) and tumor profiling tests. Direct niche overlap with Guardant Reveal MRD and Guardant360 therapy selection, particularly for biopharma CDx programs.
• Adaptive Biotechnologies: Immune-based diagnostics company with clonoSEQ MRD test (FDA-approved) and immune profiling platform. Overlaps with Guardant Reveal in MRD monitoring for hematologic malignancies, addressing similar oncologists and biopharma partners.

Others

• Bio-Techne: Life science tools and diagnostics company supplying reagents and exosome diagnostics (including ExoDx prostate test). Comparable in the broader molecular diagnostics ecosystem and serves as a supplier/adjacent player in the liquid biopsy space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/guardant-health
• Xx.com/GuardantHealth
• Facebookfacebook.com/guardanthealth

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds13 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Guardant Health